0001790340-24-000034.txt : 20240321
0001790340-24-000034.hdr.sgml : 20240321
20240321090610
ACCESSION NUMBER: 0001790340-24-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hall Brett Matthew
CENTRAL INDEX KEY: 0001870437
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40675
FILM NUMBER: 24769676
MAIL ADDRESS:
STREET 1: C/O IMMUNEERING CORPORATION
STREET 2: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immuneering Corp
CENTRAL INDEX KEY: 0001790340
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-500-8080
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, SECOND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
wk-form4_1711026361.xml
FORM 4
X0508
4
2024-03-15
0
0001790340
Immuneering Corp
IMRX
0001870437
Hall Brett Matthew
245 MAIN STREET
SECOND FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
CHIEF SCIENTIFIC OFFICER
0
Class A Common Stock
2024-03-15
4
A
0
6211
1.62
A
338896
D
Class A Common Stock
2024-03-20
4
P
0
7000
2.86
A
345896
D
The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024.
In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024.
/s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall
2024-03-21